Clinical Trials Browser

Phase 2 × GSK2256098 × 90 days × Clear all

NCT02523014 2026-03-04

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Phase 2 Recruiting

Meningioma